With significant variations in the effects of COVID-19 among various ethnic, racial, and minority groups, how do we ensure vaccine trials are accurately establishing efficacy and safety across all patient populations? Beyond the ethical considerations, diversity is a medical and scientific imperative. This peer-reviewed article identifies tools and considerations for achieving representative diversity in enrollment for COVID-19 vaccine registration trials.
Authors:
Henry J. Riordan, PhD
Chief Development Officer
Aman Khera, MBA, FTOPRA, FRAPS
VP, Regulatory Science, Strategy and Innovation
